March 3, 2020 / 7:53 AM / a month ago

BRIEF-BioInvent And Transgene Presents Data About BT-001

March 3 (Reuters) - BioInvent International AB:

* BIOINVENT AND TRANSGENE PRESENTS DATA ABOUT BT-001

* BOTH ONCOLYTIC AND ANTI-CTLA4 THERAPEUTIC STRATEGIES THAT SUPPORT BT-001 HAVE SHOWN ACTIVITY IN HUMANS BASED ON THEIR ABILITY TO INDUCE SUBSTANTIAL CHANGE IN TUMOR MICROENVIRONMENT AND ANTITUMORAL ACTIVITY

* TRANSGENE AND BIOINVENT HAVE SUBMITTED FIRST APPLICATION FOR CLINICAL TRIAL OF BT-001, AND A FIRST-IN-HUMAN TRIAL IS EXPECTED TO START BEFORE END OF 2020 IN EUROPE AND THE UNITED STATES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below